Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · Neuroactive peptides

DSIP — compound monograph

Endogenous nonapeptide. Unapproved, research supply. The Institute assesses 3 outcomes for this compound and grades the strongest at very low certainty.

Document identifier
CEI-MN-038
Series
Compound monograph
Version
1.2
Published
24 Jul 2025
Last reviewed
24 May 2026
Next review
24 May 2028
Identifier
10.71829/cei.mono.38
Certainty
Very low
Cycle
2025 Q3

§1Identification and status

§1.1Nomenclature

Preferred name
DSIP
Compound class
Endogenous nonapeptide
Assessment series
Neuroactive peptides
Synonyms and codes
delta sleep-inducing peptide · Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu · DSIP nonapeptide
Route as evaluated
Subcutaneous, intravenous or intranasal in historical studies

§1.2Chemistry

Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]

CAS registry number
62568-57-4
Molecular formula
C35H48N10O15
Average mass
848.81
Monoisotopic mass
848.33
ATC classification
not assigned

§1.3Sequence and structural notes

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH

A nonapeptide isolated in 1977 from the cerebral venous blood of rabbits during electrically induced sleep. Its name records the hypothesis under which it was found, which subsequent work has not confirmed.

§1.4Assessment status

The Institute assesses DSIP across 3 indications and grades the strongest of them at very low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.

Distribution of certainty ratingsShare of assessed outcomes at each certainty level.3assessed outcomes
HighModerateLowVery low
Figure 1. Distribution of certainty ratings across the 3 outcomes the Institute assesses for DSIP. A rating attaches to a specific population, comparator and outcome and does not transfer between them.

Table 1. Assessed outcomes for DSIP, ordered by certainty. Each row links to the per-indication evidence extract.

IndicationEffect as recordedCertaintyTrials
Alcohol use disorderSmall historical reports in withdrawal syndromes; not assessableVery low0
Cognitive performance and neuroprotectionNo assessable evidence identifiedVery low0
Sleep initiation and maintenance disordersSmall historical studies reported inconsistent effects on sleep architecture; the effect that gave the peptide its name has not been reliably…Very low1
Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.